Idera Pharmaceuticals Inc. (IDRA)

2.52
NASDAQ : Health Technology
Prev Close 2.59
Day Low/High 2.52 / 2.61
52 Wk Low/High 2.25 / 10.95
Avg Volume 365.30K
Exchange NASDAQ
Shares Outstanding 28.02M
Market Cap 72.58M
EPS -2.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Idera Pharmaceuticals (IDRA) Weak On High Volume

Idera Pharmaceuticals (IDRA) Weak On High Volume

Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a weak on high relative volume candidate

Idera Pharmaceuticals (IDRA) In A Perilous Reversal

Idera Pharmaceuticals (IDRA) In A Perilous Reversal

Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "perilous reversal" (up big yesterday but down big today) candidate

Nasdaq Strength Offsets Any Worries

Market players are unlikely to retreat until we push through 5,000.

Nasdaq's Winning Streak Nixed

Otherwise, market sticks to its recent pattern.

Interesting IDRA Call Options For April 17th

Interesting IDRA Call Options For April 17th

Investors in Idera Pharmaceuticals Inc saw new options begin trading this week, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IDRA options chain for the new April 17th contracts and identified the following call contract of particular interest.

The Trend Is Up

Fighting this market isn't a money maker.

One Reason Idera Pharmaceuticals (IDRA) Stock is Up Today

One Reason Idera Pharmaceuticals (IDRA) Stock is Up Today

Shares of Idera Pharmaceuticals (IDRA) rose in morning trading Tuesday following some insider buying at the biotech company.

Action Was Ugly, But Healthy

If the market gaps down in the morning, watch for the dip buyers.

Random, Machine-Driven Trading

Some positives, but plenty of land mines as well.

Idera Pharmaceuticals (IDRA) Is Strong On High Volume Today

Idera Pharmaceuticals (IDRA) Is Strong On High Volume Today

Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a strong on high relative volume candidate

Too Much Big Picture

Everyone's too busy talking about what might happen in 2015.

Idera Pharmaceuticals (IDRA) Stock Surges After FDA Grants Orphan Designation for Cancer Treatment

Idera Pharmaceuticals (IDRA) Stock Surges After FDA Grants Orphan Designation for Cancer Treatment

Shares of Idera Pharmaceuticals (IDRA) surged more than 15% in late afternoon trading on Monday after the FDA granted orphan designation to the company's treatment of Waldenstrom's macroglobulinemia.

Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock

Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Idera Pharmaceuticals (IDRA) Is Weak On High Volume Today

Idera Pharmaceuticals (IDRA) Is Weak On High Volume Today

Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a weak on high relative volume candidate

First Week of January 2015 Options Trading For Idera Pharmaceuticals (IDRA)

First Week of January 2015 Options Trading For Idera Pharmaceuticals (IDRA)

Investors in Idera Pharmaceuticals Inc saw new options begin trading this week, for the January 2015 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IDRA options chain for the new January 2015 contracts and identified the following call contract of particular interest.

Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent And Systemic Anti-Tumor Activity In Preclinical Models

Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent And Systemic Anti-Tumor Activity In Preclinical Models

Data Highlight Potential Opportunity to Enhance Activity of Emerging Class of Checkpoint Inhibitors With Idera's Proprietary Toll-Like Receptor Agonists

Idera Pharmaceuticals (IDRA) Is Today's Strong On High Volume Stock

Idera Pharmaceuticals (IDRA) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a strong on high relative volume candidate

TheStreet Quant Rating: D (Sell)